ArriVent BioPharma shares plunged 58% during morning trading after its lead oral cancer pill failed to meaningfully delay disease progression in a late-stage trial. The therapy, firmonertinib, was tested in untreated patients with advanced non-small-cell lung cancer. CEO Bing Yao said the data fell short of therapeutic goals.

Clinical Trial Hurdles